ASH 2023 | Mitapivat increases β-thalassemic erythroblast energy production and oxidative stress responsiveness
Lucia De Franceschi, MD, University of Verona, Verona, Italy, discusses the findings of an in vitro study into the effect of mitapivat on CD34+ derived erythroblasts from patients with β-thalassemia. This study elucidated that mitapivat significantly increases erythroid maturation and energy production while also increasing responsiveness to oxidative stress and likely having a protective effect on the β-thalassemic erythroblasts. Dr De Franceschi outlines the mechanisms which are thought to be responsible for these observations. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Bristol Myers Squibb, Agios
Board of Directors/Advisory Committee: F. Hoffmann-La Roche Ltd, Basel
